Institut De Cardiologie De Montreal

Montreal Heart Institute

Affina Biotechnologies, Inc.

Gaétan Mayer

Steve Poirier

Brent Richard Stranix

Alexander Vinitsky

Alan Berezov

The present invention relates to compounds of Table 1, which are encompassed by Formula I and/or Formula II, Ill, IV, V, or VI, and pharmaceutically acceptable salts, solvates or compositions thereof. Compounds of Table 1 are PCSK9 interacting small molecules that modulate PCSK9 activity and significantly increase low density lipoprotein receptor expression and activity, lower total circulating cholesterol and are useful for treating and delaying the onset of diseases that are associated with elevated cholesterol.

Methods of treating elevated plasma cholesterol

The present invention relates to compounds of Formula I, pharmaceutically acceptable salts, solvates or formulations thereof. Compounds of Formula I increase significantly low density lipoprotein receptor and are useful for preventing and treating of elevated cholesterol.

The present invention relates to PCSK9 inhibitors and methods of use thereof. Specifically, the invention relates to PCSK9 cell-based assay, PCSK9 inhibiting polypeptides and derivatives thereof. The invention includes pharmaceutical compositions comprising a PCSK9 inhibitor polypeptide together with a pharmaceutically acceptable carrier and method for treating cardiovascular disorders, hyperlipidemia, inflammatory diseases or inflammatory response to infection.

Growing community of inventors

Montréal, Canada

Gaétan Mayer